logo-loader

FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves

Published: 09:45 13 Jan 2023 EST

FSD Pharma devices
FSD Pharma previously repurchased nearly 2 million subordinate voting shares for cancellation at an average price of about C$1.20 over a 12-month period expiring December 30, 2022

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months. 

“FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company's interim CEO Anthony Durkacz said in a statement.

“We believe that our stock is significantly undervalued,” he added. “This will allow us to continue investing in our future, while, at the same time, also investing in the exceptional value that our own shares represent.”

READ: FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia

The 1.9 million shares figure represents about 5% of FSD’s issued and outstanding subordinate voting shares, the company said. 

The buybacks can begin on January 18, 2023, and will end January 17, 2024, or once the company reached the maximum share threshold. 

FSD noted that the company is not obligated to purchase any shares and that the program can be terminated at its discretion. 

The company previously repurchased nearly 2 million subordinate voting shares for cancellation at an average price of about C$1.20 over a 12-month period expiring December 30, 2022.

FSD Pharma is a Toronto-based biotechnology company with three drug candidates in different stages of development.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 18 minutes ago